Jazz Pharmaceuticals (JAZZ) Net Income towards Common Stockholders (2016 - 2026)
Jazz Pharmaceuticals has reported Net Income towards Common Stockholders over the past 15 years, most recently at $203.5 million for Q4 2025.
- For Q4 2025, Net Income towards Common Stockholders rose 6.49% year-over-year to $203.5 million; the TTM value through Dec 2025 reached -$263.4 million, down 146.89%, while the annual FY2025 figure was -$355.4 million, 163.27% down from the prior year.
- Net Income towards Common Stockholders for Q4 2025 was $203.5 million at Jazz Pharmaceuticals, down from $251.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $251.4 million in Q3 2025 and troughed at -$718.4 million in Q2 2025.
- A 5-year average of $9.1 million and a median of $70.4 million in 2023 define the central range for Net Income towards Common Stockholders.
- Biggest five-year swings in Net Income towards Common Stockholders: crashed 641.94% in 2022 and later skyrocketed 1116.53% in 2023.
- Year by year, Net Income towards Common Stockholders stood at -$32.3 million in 2021, then crashed by 641.94% to -$240.0 million in 2022, then surged by 139.43% to $94.6 million in 2023, then surged by 101.96% to $191.1 million in 2024, then rose by 6.49% to $203.5 million in 2025.
- Business Quant data shows Net Income towards Common Stockholders for JAZZ at $203.5 million in Q4 2025, $251.4 million in Q3 2025, and -$718.4 million in Q2 2025.